Quiz
Article
Quiz: CUA guidelines on specimen and timing considerations with genetic testing
Author(s):
Key Takeaways
- The 2023 CUA guideline highlights the significance of specimen collection and timing in prostate cancer genetic testing.
- Practical strategies are provided to optimize genetic testing outcomes, focusing on often-overlooked aspects.
Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
Accurate genetic testing in prostate cancer hinges not only on what is tested but also on how and when specimens are collected.
The 2023 CUA guideline, titled the “2023 Canadian Urological Association guideline: Genetic testing in prostate cancer”, addresses critical considerations around specimen collection and timing, providing clinicians with practical strategies to optimize testing outcomes.
This quiz, the final in our 3-part series based on the document, will delve into the guideline’s recommendations on specimen and timing considerations for genetic testing in prostate cancer. Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing!
True or False: Germline genetic testing can be initiated by non-genetic clinicians as part of mainstream clinical care.
Editor’s note: This quiz was composed with the aid of artificial intelligence tools
REFERENCE
1. Rendon RA, Selvarajah S, Wyatt AW, et al. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer. Can Urol Assoc J. 2023;17(10):314–325. doi:10.5489/cuaj.8588
